Total Payments
$630,233
2024 Payments
$72,802
Companies
36
Transactions
1,070
Medicare Patients
1,107
Medicare Billing
$102,058
Payment Breakdown by Category
Other$426,410 (67.7%)
Consulting$119,232 (18.9%)
Travel$55,911 (8.9%)
Food & Beverage$27,391 (4.3%)
Research$1,167 (0.2%)
Gifts$100.00 (0.0%)
Education$21.73 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $367,370 | 148 | 58.3% |
| Consulting Fee | $119,232 | 37 | 18.9% |
| Travel and Lodging | $55,911 | 232 | 8.9% |
| Food and Beverage | $27,391 | 611 | 4.3% |
| Honoraria | $24,750 | 17 | 3.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $20,400 | 7 | 3.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,890 | 5 | 2.2% |
| Unspecified | $1,167 | 9 | 0.2% |
| Gift | $100.00 | 1 | 0.0% |
| Education | $21.73 | 3 | 0.0% |
Payments by Type
General
$629,066
1,061 transactions
Research
$1,167
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $207,436 | 357 | $0 (2024) |
| ABBVIE INC. | $185,756 | 314 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $82,482 | 102 | $0 (2024) |
| Eisai Inc. | $52,311 | 76 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $30,130 | 24 | $0 (2020) |
| Exelixis Inc. | $17,591 | 27 | $0 (2022) |
| Dova Pharmaceuticals | $9,378 | 12 | $0 (2021) |
| Dynavax Technologies Corporation | $7,847 | 3 | $0 (2022) |
| Madrigal Pharmaceuticals | $7,572 | 11 | $0 (2024) |
| KADMON PHARMACEUTICALS LLC | $4,863 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72,802 | 111 | Gilead Sciences, Inc. ($34,448) |
| 2023 | $62,332 | 104 | Gilead Sciences, Inc. ($28,908) |
| 2022 | $93,171 | 126 | Gilead Sciences, Inc. ($33,602) |
| 2021 | $33,214 | 80 | AbbVie Inc. ($15,155) |
| 2020 | $26,946 | 55 | Gilead Sciences, Inc. ($12,003) |
| 2019 | $121,288 | 197 | AbbVie, Inc. ($36,894) |
| 2018 | $102,885 | 190 | AbbVie, Inc. ($38,839) |
| 2017 | $117,594 | 207 | Gilead Sciences Inc ($35,569) |
All Payment Transactions
1,070 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $122.04 | General |
| 12/18/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Rare Disease | ||||||
| 12/18/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $4.08 | General |
| Category: Rare Disease | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/27/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Honoraria | Cash or cash equivalent | $1,620.00 | General |
| Category: Rare Disease | ||||||
| 11/26/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/20/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: VIROLOGY | ||||||
| 11/16/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $150.17 | General |
| Category: LIVER DISEASE | ||||||
| 11/16/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Rare Disease | ||||||
| 11/16/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $49.86 | General |
| Category: VIROLOGY | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,320.00 | General |
| Category: Gastroenterology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Gastroenterology | ||||||
| 11/06/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $78.95 | General |
| Category: Rare Disease | ||||||
| 10/30/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $143.10 | General |
| Category: Rare Disease | ||||||
| 10/29/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $49.79 | General |
| Category: LIVER DISEASE | ||||||
| 10/29/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: Rare Disease | ||||||
| 10/28/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $5.28 | General |
| Category: LIVER DISEASE | ||||||
| 10/23/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| Category: HCV | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,930.00 | General |
| Category: HCV | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $205.69 | General |
| Category: HCV | ||||||
| 10/16/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $203.83 | General |
| Category: HCV | ||||||
| 10/16/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HCV | ||||||
| 10/16/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: VIROLOGY | ||||||
| 10/11/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $76.06 | General |
| Category: HCV | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $126.21 | General |
| Category: HCV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | Gilead Sciences, Inc. | $1,089 | 8 |
| STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Gilead Sciences, Inc. | $77.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 373 | 486 | $97,417 | $33,078 |
| 2022 | 6 | 301 | 405 | $70,887 | $28,512 |
| 2021 | 5 | 254 | 337 | $58,855 | $24,204 |
| 2020 | 3 | 179 | 232 | $43,990 | $16,264 |
Total Patients
1,107
Total Services
1,460
Medicare Billing
$102,058
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 108 | 182 | $39,312 | $15,074 | 38.3% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 72 | 88 | $26,400 | $6,445 | 24.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $11,916 | $3,747 | 31.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 33 | $9,603 | $3,676 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 52 | $7,644 | $3,159 | 41.3% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 33 | 34 | $2,176 | $619.01 | 28.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 51 | 61 | $366.00 | $358.68 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 105 | 176 | $38,016 | $16,256 | 42.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $13,571 | $4,469 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 35 | $10,185 | $4,449 | 43.7% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 84 | 100 | $6,400 | $2,162 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 17 | $2,499 | $1,069 | 42.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 27 | 36 | $216.00 | $106.83 | 49.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 87 | 153 | $33,048 | $14,362 | 43.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 49 | 49 | $16,219 | $6,095 | 37.6% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 81 | 93 | $5,952 | $2,290 | 38.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 21 | 24 | $3,528 | $1,403 | 39.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 16 | 18 | $108.00 | $54.00 | 50.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 86 | 132 | $28,512 | $10,185 | 35.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 34 | 34 | $11,254 | $4,203 | 37.3% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2020 | 59 | 66 | $4,224 | $1,876 | 44.4% |
About Dr. Richard Manch, M.D
Dr. Richard Manch, M.D is a Gastroenterology healthcare provider based in Glendale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043289341.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Manch, M.D has received a total of $630,233 in payments from pharmaceutical and medical device companies, with $72,802 received in 2024. These payments were reported across 1,070 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($367,370).
As a Medicare-enrolled provider, Manch has provided services to 1,107 Medicare beneficiaries, totaling 1,460 services with total Medicare billing of $102,058. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology
- Location Glendale, AZ
- Active Since 03/17/2006
- Last Updated 01/12/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1043289341
Products in Payments
- Epclusa (Drug) $140,103
- MAVYRET (Drug) $77,059
- Mavyret (Drug) $74,306
- OCALIVA (Drug) $58,785
- Lenvima (Drug) $52,208
- OCA (Drug) $23,696
- Cabometyx (Drug) $16,817
- Nexavar (Drug) $16,568
- Vemlidy (Drug) $14,385
- Stivarga (Drug) $13,439
- Viekira (Drug) $12,797
- Doptelet (Drug) $9,378
- Livdelzi (Drug) $8,130
- Heplisav-B (Drug) $7,847
- XIFAXAN (Drug) $7,387
- REZDIFFRA (Drug) $7,367
- CREON (Drug) $6,938
- Vosevi (Drug) $5,743
- ZEPATIER (Drug) $3,730
- Wako HCC Biomarker(s) DCP and AFP-L3 (Device) $3,640
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Glendale
Frederick Boghossian, M.d, M.D
Gastroenterology — Payments: $175,402
Gastroenterology $175,402
Armine Sarkisian, M.d, M.D
Gastroenterology — Payments: $124,705
Gastroenterology $124,705
Mr. James Tabibian, M.d, M.D
Gastroenterology — Payments: $39,283
Gastroenterology $39,283
Dr. Vikram Singh, M.d, M.D
Gastroenterology — Payments: $34,147
Gastroenterology $34,147
Dr. Rimma Shaposhnikov, M.d, M.D
Gastroenterology — Payments: $23,780
Gastroenterology $23,780
Dr. Mehdi Khorsandi, M.d, M.D
Gastroenterology — Payments: $20,237
Gastroenterology $20,237